Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Kana, Hara, Munechika, Iwakami, Shin-ichiro, Genda, Takuya, Iwakami, Naoko, Miyashita, Yosuke, Fujioka, Masahiro, Sasaki, Shinichi, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911765/
https://www.ncbi.nlm.nih.gov/pubmed/31735738
http://dx.doi.org/10.2169/internalmedicine.2591-18
_version_ 1783479320259330048
author Kurokawa, Kana
Hara, Munechika
Iwakami, Shin-ichiro
Genda, Takuya
Iwakami, Naoko
Miyashita, Yosuke
Fujioka, Masahiro
Sasaki, Shinichi
Takahashi, Kazuhisa
author_facet Kurokawa, Kana
Hara, Munechika
Iwakami, Shin-ichiro
Genda, Takuya
Iwakami, Naoko
Miyashita, Yosuke
Fujioka, Masahiro
Sasaki, Shinichi
Takahashi, Kazuhisa
author_sort Kurokawa, Kana
collection PubMed
description The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity. Despite the frequency of hepatotoxicity, there is only limited information available regarding the pathophysiology and treatment. We herein report a 48-year-old man with lung adenocarcinoma who was treated with pembrolizumab and developed cholestatic liver injury. In this case, the importance of evaluating the histology of hepatotoxicity and the effectiveness of ursodeoxycholic acid for cholestatic liver injury is indicated.
format Online
Article
Text
id pubmed-6911765
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-69117652019-12-16 Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma Kurokawa, Kana Hara, Munechika Iwakami, Shin-ichiro Genda, Takuya Iwakami, Naoko Miyashita, Yosuke Fujioka, Masahiro Sasaki, Shinichi Takahashi, Kazuhisa Intern Med Case Report The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity. Despite the frequency of hepatotoxicity, there is only limited information available regarding the pathophysiology and treatment. We herein report a 48-year-old man with lung adenocarcinoma who was treated with pembrolizumab and developed cholestatic liver injury. In this case, the importance of evaluating the histology of hepatotoxicity and the effectiveness of ursodeoxycholic acid for cholestatic liver injury is indicated. The Japanese Society of Internal Medicine 2019-11-15 2019-11-15 /pmc/articles/PMC6911765/ /pubmed/31735738 http://dx.doi.org/10.2169/internalmedicine.2591-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kurokawa, Kana
Hara, Munechika
Iwakami, Shin-ichiro
Genda, Takuya
Iwakami, Naoko
Miyashita, Yosuke
Fujioka, Masahiro
Sasaki, Shinichi
Takahashi, Kazuhisa
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title_full Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title_fullStr Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title_full_unstemmed Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title_short Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
title_sort cholestatic liver injury induced by pembrolizumab in a patient with lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911765/
https://www.ncbi.nlm.nih.gov/pubmed/31735738
http://dx.doi.org/10.2169/internalmedicine.2591-18
work_keys_str_mv AT kurokawakana cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT haramunechika cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT iwakamishinichiro cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT gendatakuya cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT iwakaminaoko cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT miyashitayosuke cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT fujiokamasahiro cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT sasakishinichi cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma
AT takahashikazuhisa cholestaticliverinjuryinducedbypembrolizumabinapatientwithlungadenocarcinoma

Ejemplares similares